Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fluticasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 14/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.70 |
| ▸ | PGR | P06401 | 4/20 | 0.70 |
| ▸ | AR | P10275 | 4/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | CNR1 | P21554 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluticasone SCHEMBL14135286 | 0.95 | NR3C1 (1.00) | NR3C1CYP3A4PGRARHIF1A | |
| Fluticasone SCHEMBL65401 | 0.95 | NR3C1 (1.00) | NR3C1CYP3A4PGRARHIF1A | |
| Fluticasone SCHEMBL4069 | 0.95 | NR3C1 (1.00) | NR3C1CYP3A4PGRARHIF1A | |
| Fluticasone SCHEMBL2231799 | 0.95 | NR3C1 (1.00) | NR3C1CYP3A4PGRARHIF1A | |
| Fluticasone SCHEMBL27674669 | 0.94 | NR3C1 (0.95) | NR3C1CYP3A4PGRARHIF1A | |
| Fluticasone SCHEMBL28888601 | 0.94 | NR3C1 (0.98) | NR3C1CYP3A4PGRARHIF1A | |
| Fluticasone SCHEMBL28821706 | 0.94 | NR3C1 (0.98) | NR3C1CYP3A4PGRARHIF1A | |
| Fluticasone SCHEMBL896670 | 0.94 | NR3C1 (0.93) | NR3C1CYP3A4PGRARHIF1A | |
| Fluticasone SCHEMBL28935320 | 0.94 | NR3C1 (0.97) | NR3C1CYP3A4PGRARHIF1A | |
| Fluticasone SCHEMBL28768408 | 0.92 | NR3C1 (0.91) | NR3C1CYP3A4PGRARHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8758816-B2 | Compositions comprising azelastine and methods of use thereof | MEDA PHARMACEUTICALS INC. (US) | 2014-06-24 | — | — | US | claimed |
| US-20130104881-A1 | Stabilized Metered Dose Inhaler | LABORATORIO PABLO CASSARA S.R.L. (AR) | 2013-05-02 | — | — | US | claimed |
| US-20120204871-A1 | Stable, non-corrosive formulations for pressurized metered dose inhalers | VEGA JULIO CESAR (AR) | 2012-08-16 | — | — | US | claimed |
| US-20120207685-A1 | Non-ozone depleting medicinal formulations with low greenhouse effect | aboratorio Pablo Cassara S.R.L. (AR) | 2012-08-16 | — | — | US | claimed |
| EP-2486914-A2 | Stable, non-corrosive formulations for pressurized metered dose inhalers | Laboratorio Pablo Cassara S.r.L. (AR) | 2012-08-15 | — | — | EP | claimed |
| US-20100152147-A1 | Compositions Comprising Azelastine and Methods of Use Thereof | MEDA PHARMACEUTICALS INC. | 2010-06-17 | — | — | US | claimed |
| US-8758816-B2 | Compositions comprising azelastine and methods of use thereof | MEDA PHARMACEUTICALS INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130104881-A1 | Stabilized Metered Dose Inhaler | LABORATORIO PABLO CASSARA S.R.L. (AR) | 2013-05-02 | — | — | US | disclosed |
| US-20120207685-A1 | Non-ozone depleting medicinal formulations with low greenhouse effect | aboratorio Pablo Cassara S.R.L. (AR) | 2012-08-16 | — | — | US | disclosed |
| US-20100152147-A1 | Compositions Comprising Azelastine and Methods of Use Thereof | MEDA PHARMACEUTICALS INC. | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152147-A1 | Compositions Comprising Azelastine and Methods of Use Thereof | TAS2R5, HRH2, IL5 | MEN1 2259/4885KMT2A 3177/4885NR3C1 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.